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Background: It is unclear to what extent uremic toxins participate in inflammatory responses and the activities of
deiodinases, as well as the effects of deiodinases on inflammatory cytokines.
Materials and methods: Hepatocellular carcinoma cell lines (HepG2) were transfected with small interfering
ribonucleic acid (siRNA) specific for deiodinase type 1 (DIO1) and cultured with or without uremic toxins. The
mRNA expression of DIO1, interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α was detected by quantitative
real-time PCR. The presence of selenoprotein M (SelM) and DIO1 was assessed by western blotting. Sonicate
deiodinase activities in HepG2 cells were measured by a dithiothreitol-stimulated assay. The NF-κB, AP-1 and CREB-1
inflammatory signal pathways were confirmed by EMSA.
Results: After culturing for 24 h, the mRNA expression of DIO1 was significantly decreased by the specific siRNA
(reduced by 76%, P = 0.0002). Uremic toxins significantly increased the mRNA expression (P < 0.01) of IL-1β, IL-6 and
TNF-α and inhibited DIO1 mRNA expression (P < 0.01) compared with controls. Suppression of DIO1 by siRNA
significantly decreased the mRNA expression of IL-1β and IL-6 (P < 0.05) but not TNF-α (P = 0.093). Uremic toxins
and specific siRNA synchronously reduced the protein expression of SelM and DIO1.
Conclusions: Uremic toxins activate the expression of inflammatory cytokines. The major findings of this study
indicate that the uremic toxins, more than inflammatory cytokines, play direct inhibitory roles in DIO1 enzyme
activity, which then provides a negative feedback to the growing accumulation of inflammatory cytokines.
Keywords: Uremic toxins, Small interfering ribonucleic acid, Inflammatory cytokines, DeiodinaseIntroduction
Nonthyroidal illness syndrome (NTIS), also known as eu-
thyroid sick syndrome, refers to the characteristic changes
in thyroid hormone levels, typically decreases in serum
3,5,3’-triiodothyronine (T3) levels and a reduction in the
T3/reverse T3 (rT3) ratio, in critically ill patients. How-
ever, the pathogenesis of these imbalances in endocrine
hormones is not fully understood [1]. The iodothyronine
deiodinases (DIOs) modify the bioactivity of thyroid hor-
mone by controlling the concentrations of thyroxine (T4)
and its active form, T3. In humans, 80-90% of circulating* Correspondence: gaosixu@163.com; qsl9995@aliyun.com
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unless otherwise stated.T3 is derived from the pro-hormone T4, and the conver-
sion from T4 to T3 is catalyzed by both type 2 deiodinase
(DIO2) and, primarily, by type 1 (DIO1) via outer-ring
deiodination [2]. The third deiodinase, DIO3, prevents T4
activation and terminates T3 actions. DIO1 is susceptible
to inhibitory drugs, as well as changes in the thyroid hor-
mone status. The prompt reduction of circulating T3
levels observed in NTIS must be, at least in part, due to
the decreased peripheral conversion by DIO1 and/or
DIO2 [3].
Available data suggest that interleukin (IL)-1β, IL-6,
and tumor necrosis factor (TNF)-α play roles in the
pathogenesis of NTIS. Serum IL-6 concentrations were
negatively correlated with free T3 (FT3) and positively
with rT3 concentrations [4]. Serum IL-6 is often in-
creased in NTIS, and the serum level of this cytokine isThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stage renal disease (ESRD) [5]. A single intravenous in-
jection of IL-6 to healthy humans results in a transient
decline in serum T3 and an increase in rT3; these
changes mimic NTIS [6]. DIO1 is positively regulated by
T3 and expressed in liver, kidney, thyroid, and pituitary.
However, studies in mouse hepatic cells have shown that
TNF-α, IL-1β, and IL-6 induce increases in DIO1 acti-
vity [7]. The role of DIO1 in NTIS is also being chal-
lenged because of the publication of data in which
DIO1-deficient mice maintained normal T3 levels, which
suggests that the decrease in liver DIO1 could be a
consequence rather than a cause of reduced T3 [8].
Therefore, a better understanding of the mechanisms
underlying altered DIO activities during uremic toxins
exposure and illness is necessary to understand NTIS
and ultimately improve the disease outcome in patients
with chronic kidney disease.
Selenium (Se), which assists cells in resisting oxidative
stress, is an essential trace element for mammals and may
function as a redox regulator. Up-expression of selenopro-
tein M (SelM) in rats enhanced the activity of antioxidant
enzymes such as glutathione peroxidase (GSH-Px) and
superoxide dismutase (SOD) [9]. Moreover, SelM knock-
down resulted in increased reactive oxidative stress (ROS),
which further demonstrated the functional importance of
SelM in preventing oxidative stress [10]. The addition of
the antioxidant N-acetyl-cysteine (NAC), which restores
intracellular GSH levels, prevented the IL-6-induced in-
hibitory effects on T3-mediated production, suggesting
that the effect of IL-6 on DIO1 is mediated by oxidative
stress [11]. Although little is known about the role of
DIO2 in NTIS, all three deiodinases requires an endo-
genous cofactor, most likely GSH, which acts as a re-
ducing agent to release iodine from the selenocysteine
residue and regenerate the enzyme. However, little is
known about the relationship between deiodinase and
SelM during oxidative stress and inflammation.
DIO1 is susceptible to inhibitory drugs. It is unclear to
what extent the uremic toxins play roles in the inflam-
matory responses and deiodinase activities in patients
with chronic renal failure. In this study, by mimicking
the internal environment of patients with chronic renal
failure, we examine the effects of small interfering RNAs
(siRNA) and uremic toxins on the expression and func-
tion of DIO1 and inflammatory cytokines. In this way,
we are able to unveil the interaction among inflamma-
tory cytokines, the activities of DIO1 and their possible
signaling pathways during treatment with uremic toxins.
Materials and methods
HepG2 cell culture
HepG2 cells (human hepatoma) obtained from the Chinese
Academy of Medical Sciences were grown in Dulbecco’smodified Eagle’s medium (DMEM) + 10% fetal bovine
serum (FBS, v/v) + 100 nmol/l Se containing 100 units/ml
penicillin and 30 μg/ml streptomycin under 5% CO2.
RNA interference of DIO1
For the transfection of siRNAs, HepG2 cells were cultured
and then transfected at a cell confluency of approximately
50% with Lipofectamine 2000, as indicated by the manu-
facturer’s instructions. Six hours after transfection, cells
were collected and processed for quantitative real-time
PCR (qRT-PCR) and fluorescence microscopy to evaluate
the efficiency of siRNA knockdown. The siRNAs for
DIO1 were chemically synthesized by Sangon Biotech,
Shanghai, China. The siRNA sequences used were selec-




Seq3, 5’-GGCUGUGACUUGAUUCAAATT-3’ and 5’-UU
UGAAUCAAGUCACAGCCTT-3’. Sequence 5’-UUCUC
CGAACGUGUCACGUTT-3’ and 5’-ACGUGACACGU
UCGGAGAATT-3’ for negative control FAM. Sequence
for negative control, 5’-UUCUCCGAACGUGUCACGU
TT-3’ and 5’-ACGUGACACGUUCGGAGAATT-3’. 5’-
GUAUGACAACAGCCUCAAGTT-3’ and 5’-CUUGAGG
CUGUUGUCAUACTT-3’ for GAPGH positive control.
After evaluation by qRT-PCR and fluorescence micros-
copy, Seq3 was selected as the final siRNA because of its
optimal interference efficiency above 76%.
Study groups
The study groups were configured as following: Controls,
DMEM+ 10% FBS + 100 nmol/l Se; Toxins, controls +
80 μmol/l urea + 200 μmol/l creatinine + 10 nmol/l uric
acid + 2 pg/ml parathyrin and 20 μmol/l spermidine (final
concentrations); SiRNAs, controls + siRNAs; and the com-
bined toxins and siRNAs group. All cells were cultured
and collected for analysis at 3 h, 6 h, 12 h and 24 h.
RNA extraction and qRT-PCR
Total RNA was isolated from HepG2 cells using an
RNeasy mini kit (Qiagen, Texas, USA) according to the
manufacturer’s specifications. Total RNA from each sam-
ple was reverse-transcribed with random primers using a
StrataScript reverse transcriptase kit (Stratagene, California,
USA) followed by qRT-PCR analysis. The primers for
DIO1 amplification were 5’-TGGTGGTGATGATGGGT
GAG-3’ and 5’-GCATTGCTGGTGCCTATTGTT-3’. The
primers for IL-1β were 5’-ACGAATCTCCGACCACCA
CTA-3’ and 5’-GCACATAAGCCTCGTTATCCC-3’. IL-6
were 5’-TGAGGAGACTTGCCTGGTGAA-3’ and 5’-GC
ATTTGTGGTTGGGTCAGG-3’. The primers for TNF-α
gene amplification were 5’- GGCAGTCAGATCATC
TTCTCGAA-3’ and 5’- TGAAGAGGACCTGGGAGTAG
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amplification were 5’-GGAGTCCACTGGCGTCTTC-3’
and 5’-GCTGATGATCTTGAGGCTGTTG-3’. The qRT-
PCR was performed with Taqman One-step RT-PCR
Master Mix Reagents on an ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster city, CA).
The singularity and specificity of amplifications were
evaluated by Dissociation Analysis Software (ABI PRISM
Com., CA, USA). All reactions were performed in tripli-
cate. Relative expression levels and standard deviations
were calculated using the comparative method.DIO1 activity
To determine the activity of DIO1, HepG2 cells were pre-
pared and assayed, as previously described [12]. Cells were
washed with HBSS and homogenized in buffer containing
250 mmol/l glucose, 20 mmol/l Hepes, 1 mmol/l EDTA,
and 1 mmol/l dithiothreitol by ultrasonication (ten pulses
of 0.5 s at 200 W). The proteins were measured by a mo-
dified Bradford assay (Bio-Rad, Munich, Germany). Sam-
ples were then incubated in a total volume of 200 μl
containing 1 μmol/l rT3, 50 000 cpm/tube [3’,5’-125I]rT3
(labeled using 17 Ci/mg carrier-free 125I from PerkinElmer,
Massachusetts, USA), 0.05 mg microsomal protein/ml,
2 mmol/l EDTA, and 5 mmol/l dithiothreitol and incu-
bated for 30 min at 37°C, followed by trichloroacetic acid
(TCA) precipitation of media and counting of the 125I−
remaining in the supernatant. Non-specific cell deio-
dination was determined by the addition of 100 μmol/l
propylthiouracil (PTU). All samples were measured in
triplicate.Western blotting
Cells were harvested with ice-cold PBS and centrifuged
at 14000 × g for 4 min at 4°C. Nuclear and cytosolic ex-
tracts were prepared using a Nuclear and Cytoplasmic
Protein Extraction Kit (Pierce Biotechnology, Rockford,
Illinois) according to the manufacturer’s instructions.
Protein concentrations were measured by using a bicin-
choninic acid protein assay kit (Pierce Biotechnology,
Rockford, Illinois). Protein extractions of 50 μg were re-
solved in 10% SDS-PAGE and transferred onto immuno-
blot polyvinylidene difluoride membranes. Briefly, the
blots were blocked with 5% nonfat milk, washed with
Tris-buffered saline with 0.1% Tween (TBS-T), and incu-
bated overnight at 4°C with primary rabbit antibodies
DIO (1:400) (Santa Cruz Biotechnology, Dallas, Texas),
SelM (1:1000) (Abcam, Cambridge, UK) and β-actin (the
marker of cytoplasm fraction) (1:2000) (Santa Cruz
Biotechnology). Blots were then washed in TBS-T and
incubated with horseradish peroxidase-labeled secondary
goat anti-rabbit (1:2000; Santa Cruz Biotechnology) for 1 h
at room temperature. Western analysis of quantificationwas performed with Image J (National Institutes of
Health/USA).
Electrophoretic mobility shift assay (EMSA)
After culturing for 12 h, nuclear extracts were prepared
using nuclei lysis solution, and the EMSA was performed
with the NF-κB Gel Shift Assay System according to the
manufacturer’s instructions. Protein concentrations were
determined using the BioRad protein reagents. The NF-κB
double-stranded consensus oligonucleotide 5’-AGTT
GAGGGGACTTTCCCAGGC-3’ was end-labeled with
Cy5.5-lectin. Unincorporated nucleotides were removed
by passing the reaction mixture through a Sephadex G-25
spin column (Amersham-Pharmacia, Uppsala, Sweden).
Purified Cy5.5-lectin-labeled probe was incubated in 25 μl
total volume binding reaction mixture containing 5 μg
nuclear extracts at room temperature for 30 min. DNA-
protein complexes were separated by electrophoresis
through a 6% non-denaturing acrylamide:bis-acrylamide
(37.5:1) gel in 0.5 × Tris-borate/EDTA (TBE) for 2 h at
150 V. The NF-κB 5’-GCCTGGGAAAGTCCCCTCA
ACT-3’ unlabeled double-stranded consensus oligonuc-
leotide was included in 2-fold molar excess over the
amount of Cy5.5-lectin-labeled NF-κB probe to detect
specific and non-specific DNA-protein interactions. The
composition of the complexes was determined by super-
shift assays. Quantification was performed with Image J
(National Institutes of Health/USA). The double-stranded
consensus oligonucleotide was 5’-CGCTTGATGACT
CAGCCGGAA-3’ for the acute protein (AP)-1 assay, and
the unlabeled double-stranded consensus oligonucleotide
was 5’-TTCCGGCTGAGTTACCAAGCG-3’ for its com-
petition. Sequence 5’-AGAGATTGCCTGACGTCAGA
GAGCTAG-3’ and unlabeled 5’-CTAGCTCTCTGACGT
CAGGCAATCTCT-3’ were used for the cAMP response
element-binding protein (CREB)-1.
Measurement of IL-6 in culture supernatants by ELISA
IL-6 production was measured in culture supernatants
by using a Human IL-6 Quantikine ELISA kit (R&D sys-
tems, Minneapolis, MN) according to the manufacturer’s
instructions. All samples were measured in triplicate.
Statistical analysis
Raw mRNA expression data were computed by 2−△Ct
formula with values normalized to GAPDH [13]. All data
were presented as the mean ± standard deviation (SD) of
triplicate experiments, unless otherwise specified. Data
were analyzed by using Student’s 2-tailed T test or one-
way ANOVA, followed by post-hoc Duncan multiple
range test when F values were significant. SPSS software
version 17.0 for Windows was used for statistical ana-
lysis. A P value less than 0.05 was considered significant.
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Estimating the mRNA expression by qRT-PCR
We evaluated the effects of uremic toxins and specific
siRNA treatment on the temporary mRNA expression of
DIO1 and inflammatory cytokines. The inhibition of
DIO1 by specific siRNA treatment significantly decreased
its mRNA expression compared with controls (P < 0.01)
and uremic toxins (P < 0.05) (Figure 1A). Although the
relative expression level was lower, 10−5 to GAPDH,
uremic toxins markedly downregulated the DIO1 mRNA
expression within the 24 h culture period. Uremic toxins
significantly increased the mRNA expression of IL-1β
(P < 0.05), IL-6 (P < 0.01) and TNF-α (P < 0.01) compared
with controls (Figure 1B, C and D). Specific siRNA treat-
ment for DIO1 notably decreased the mRNA levels of
IL-1β (P < 0.05) and IL-6 (P < 0.05) but not TNF-α
(P = 0.093). The quantitative values of IL-1β and TNF-α
mRNA expression in HepG2 cells cultured with uremic
toxins and specific siRNA were more prominently re-
duced (P < 0.05) than those cultured with only uremic
toxins (P < 0.05), but that of IL-6 was not (P = 0.18). This
result could be explained by the relatively higher mRNA
expression compared with GAPDH (10−3); therefore, spe-
cific siRNA treatment may play a contrasting role to that
of uremic toxins.Figure 1 Estimating the mRNA expression by quantitative real-time P
cells. Samples were measured in triplicate, and data are shown as the meaDIO1 activities of HepG2 cells
The deiodinase activities in the presence of dithiothreitol
(DTT) were estimated for the maximal function of
DIO1 in HepG2 cells. As indicated in Figure 2, although
T3 production in the siRNA treatment did not differ
from that in the case of treatment with siRNA and
toxins (P = 0.073), significant decreases in T3 production
were observed in the group treated with uremic toxins
(the DIO1 activities decreased by nearly 27%, P < 0.05)
and group siRNA (the DIO1 activities decreased by
approximately 59%, P < 0.01) compared with controls.
The decrease in DIO1-catalyzed T4-to-T3 conversion in-
duced by siRNA and/or uremic toxins was measured at
12 h into incubation. Consistent with the results of qRT-
PCR mRNA analysis, the specific siRNA treatments
silenced the activities of the corresponding proteins.
Western blotting analysis of DIO1 and SelM expression
At relatively low expression levels, the DIO1 protein
(28 KDa) expression in HepG2 cells was significantly
inhibited by approximately 28% (P < 0.05) after treatment
with uremic toxins and approximately 58% (P < 0.01) after
treatment with the specific siRNA (Figure 3A), compared
with controls. Because all 3 deiodinases and SelM are
selenocysteine-containing, thiol-interacting oxidoreductases,CR of DIO1 (A), IL-1β (B), IL-6 (C), and TNF-α (D) in cultured HepG2
n ± standard deviation.
Figure 2 Uremic toxins and/or siRNA induced decreases in
DIO1 activities of HepG2 cells cultured for 12 h were paralleled
by the declines in their respective expression of mRNA and
protein (Figure 3). Samples were measured in triplicate, and data
are shown as the mean ± standard deviation.
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the redox changes. Therefore, we also evaluated SelM
protein expression by immunoblotting. SelM protein (16.2
KDa) expression was significantly inhibited by appro-
ximately 40% (P < 0.05) after treatment with uremic toxins
and approximately 92% (P < 0.01) after treatments with
the specific siRNA (Figure 3B), compared with controls.
Confocal microscopy studies have indicated that DIO1
is localized in the plasma membrane, with its activeFigure 3 Effects of uremic toxins and specific siRNA treatment on He
Normalized densitometric data of the DIO1 (28 KDa, A) and SelM (16.2 KDa
W1 = toxins, W2 = siRNA, and W3 = toxin + siRNA. Data are shown as the mcenter predicted to be in the cytosol. IL-6 can alter
GSH/oxidized GSH shuttling and recycling, which leads
to intracellular GSH depletion as a result of ROS forma-
tion [14]. Because the decreased SelM protein expression
induced by uremic toxins and/or siRNA was paralleled
by the DIO1 activities, which was also confirmed by
western blot, we speculated that the reduction in DIO1
function in HepG2 cells could be due to the inhibition
of GSH by the generation of ROS and subsequent oxida-
tive stress. Therefore, we deduced that, except for the in-
hibitive effects on DIO1 mRNA expression and enzyme
activities by uremic toxins, the subsequently produced
inflammatory cytokines, especially IL-6, may also play
important roles in the suppression of DIO1.
Inflammatory signal pathways by EMSA
For DNA binding activities that were unclear, extracts
were evaluated by EMSA, and we observed that the
uremic toxins and/or specific siRNA treatments inacti-
vated the inflammatory signals involving NF-κB, AP-1
and CREB-1 pathways. In contrast to controls, there was
a prominent activation of NF-κB in HepG2 cells cul-
tured with uremic toxins (P < 0.05) and inhibition in
cells with specific siRNA treatment (P < 0.05, Figure 4A).
The NF-κB/DNA complex was displaced by an excess of
unlabeled NF-κB, and not by Cy5.5-lectin-labeled NF-κB
probe, demonstrating the specificity of the NF-κB/DNA
binding complex.pG2 cells cultured for 12 h (n = 4 in each group) by western blot.
, B) bands obtained from the protein extractions. W0 = controls,
ean ± standard deviation.
Figure 4 Effects of uremic toxins and specific siRNA treatment on NF-κB (A), AP-1 (B) and CREB-1 (C) activation by EMSA in HepG2 cells
cultured for 12 h (n = 4 in each group). Normalized densitometric data of the NF-κB, AP-1, and CREB-1 bands obtained from the extracts of
proteins with unclear interactions. N = negative control, A = controls, B = toxins, C = siRNA, and D = toxin + siRNA. Data are shown as the
mean ± standard deviation.
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not only regulated by NF-κВ but also by activator pro-
tein AP-1 [15]. Additionally, CREB is a known inducer
of DIO1, DIO2 and DIO3 gene transcription [16,17].
Therefore, we speculated that AP-1 and CREB pathways
are also involved in the inflammatory responses. Com-
pared with controls, specific siRNA treatment reduced
AP-1 signals by approximately 28% (P < 0.05, Figure 4B)
and approximately 32% for CREB-1 (P < 0.05, Figure 4C).
Interestingly, paralleled by the mRNA expression of
inflammatory cytokines and confirmed by qRT-PCR,
uremic toxins significantly increased the production of
AP-1 protein (P < 0.05), but not CREB-1 (P = 0.38).ELISA screening for IL-6
Concentrations of IL-6 in culture supernatants, mea-
sured by ELISA, increased time-dependently during the
12 h culturing period. In contrast to the stimulated se-
cretion of IL-6 due to uremic toxins (P < 0.05 versus
controls), specific DIO1 siRNA treatment (P < 0.01 ver-
sus controls) depressed the production of IL-6 in HepG2
cells (Figure 5). Interestingly, there is no distinct differ-
ence in IL-6 production between cells cultured with
uremic toxins and those cultured with uremic toxins
and specific siRNA (P = 0.13). This phenomenon was ob-
served previously in the quantitative analysis of IL-6
mRNA expression, which has been interpreted by the
Figure 5 ELISA quantification of IL-6 concentrations in culture
supernatants of HepG2 cells. Data are shown as mean values, and
all samples were measured in triplicate.
Figure 6 The simplified possible pathogenesis between
inflammation and oxidative stress in patients with chronic
kidney disease (CKD). AGEs: advanced glycation end products,
AOPP: advanced oxidation protein products, NADPH: nicotinamide
adenine dinucleotide phosphate.
Figure 7 Proposed mechanisms of the interaction between
inflammatory cytokines, oxidative stress and deiodinase
activities in patients with chronic renal failure. (+): promoting
effect, (-): inhibitory effect.
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by uremic toxins. The stimulation of IL-6 by uremic
toxins and the inhibitory effects induced by specific
siRNA were consistent with the results from EMSA,
which further confirmed that the uremic toxins play
pivotal roles in the inflammatory responses of patients
with chronic renal failure.
Discussion
IL-6 decreases hepatocyte thyroxine deiodinase expres-
sion and inhibits thyroid function through the binding
of IL-6 and soluble IL-6 receptor (sIL-6R) complex to
gp130 [18]. The infusion of recombinant TNF-α in hu-
man also produced a significant decrease in serum T3
[19]. Cytokines inhibit the mRNA expression and func-
tion of DIO1 in HepG2 cells, and studies of rat he-
patocyte cells has indicated that IL-1 and IL-6 impair
T3-mediated induction of DIO1 expression by a me-
chanism involving thyroid hormone receptor interaction
[20,21]. Blocking with IL-6, however, failed to induce the
euthyroid sick syndrome (also called NTIS) in animal
models [22]. In an experimental IL-6 knock-out mouse
study, a less distinct decrease in T3 levels and alterna-
tion of liver D1 activity were found after administration
of lipopolysaccharide (LPS), which prompted questions
regarding the clinical findings [23].
Therefore, it is necessary to observe the exact mecha-
nisms of interaction between inflammatory cytokines and
DIOs from a new perspective in which we discuss the
relationship inversely from DIOs to cytokines by gene
silencing of deiodinase. Moreover, the effects of uremic
toxins per se on inflammatory responses and DIO acti-
vities in critical illness have not been previously investi-
gated. Confirmed by qRT-PCR, DTT estimation of DIO1
activities, western blot, EMSA and ELISA assays, we
concluded that the specific siRNA treatment not only de-
creased the DIO1 mRNA expression and enzyme activities
but also played an inhibitory role in the production ofinflammatory cytokines in cultured HepG2 cells. The
major finding of the present study is that the uremic
toxins per se, more than inflammatory cytokines, play a
pivotal role in the inhibition of DIO1 activity.
Oxidative stress due to augmented ROS or reactive
nitrogen species generation is characteristic of critical
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play decreased plasma and intracellular levels of antioxi-
dant scavenging molecules, such as GSH, as well as
reduced activity of the antioxidant enzymatic system in-
volving ROS detoxification [24]. By increasing intracellu-
lar GSH concentrations, NAC completely diminished
the inhibitory effect of IL-6 on D1 and D2-mediated T4
to T3 conversion [11]. The effects of selenium deficiency
on hepatic and thyroidal DIO1 and selenium-dependent
glutathione peroxidase (GSH-Px) activities have been
studied in weanling rats. In selenium-deficient rats, he-
patic DIO1 activity was reduced to 11%. Their hepatic
and GSH-Px activities were also reduced [25]. Con-
firmed by qRT-PCR, DTT estimation of DIO1 activities
and western blot analyses, uremic toxins and specific
siRNA synchronously reduced the protein expression of
SelM and DIO1, which further verified the role of in-
flammatory cytokines in decreasing deiodinase activities.
NF-κВ activation is a major pathway involved in the
process of inflammation where IL-1 and TNF-α is pivotal
players. Activation of NF-κВ promotes the release of in-
flammatory mediators including IL-1, IL-6 and TNF-α
[26]. TNF-α activates NF-κB pathways, and then inhibits
DIO1 mRNA and enzyme activity in HepG2 cells [27]. In-
flammatory cytokines such as IL-1 and TNF-α were not
only regulated by NF-κВ but also by both activator protein
AP-1 [15] and CREB, a known inducer of DIOs gene tran-
scription [17]. The present EMSA results suggest that
uremic toxins promoted the NF-κВ, AP-1 and CREB pro-
tein expression, most likely by increasing the production
of inflammatory cytokines.
Although the exact mechanisms of inflammation and
oxidative stress have not been accurately elucidated in
CKD patients, a number of the following factors appear to
be involved, including uremic toxins [28], rennin-angio-
tensin system [29], hypertension [30], underlying diseases
(diabetes and autoimmune diseases, etc.) [31], infection,
iron overload [32], and antioxidant deficiency [33], etc.
Oxidative stress can provoke inflammation by activating
NF-κB and causing the subsequent generation of pro-
inflammatory cytokines (Figure 6) [34]. The production
and release of reactive oxygen or nitrogen species and
chlorine by the activated immune cells, in turn, promotes
oxidative stress [35]. However, the effects of uremic
toxins per se on deiodinase activities and inflammatory
responses, as well as the converse effect of deiodinases
on inflammatory cytokines, have not been previously
investigated.
As indicated in Figure 7, inflammatory cytokines,
uremic toxins, and oxidative stress play an inhibitory
role in the activation of deiodinases. The present fin-
dings provide a possible mechanistic explanation for the
decreased enzyme activities and increased inflammatory
cytokines observed in the mimicked circumstances ofchronic renal failure. The suppression of deiodinase ac-
tivities conversely resulted in a strong inhibitory effect
on the production of inflammatory mediators, providing
negative feedback to avoid the cascading effect and to
establish a new balance in the internal environment of
patients with chronic renal failure.
There are several limitations in the present study. First,
siRNA for DIO1 was transient, and vector-transfected
siRNA should be investigated for a longer period in
in vivo animal experiments. Second, there are three types
of deiodinases, therefore, siRNA for DIO2 and/or DIO3
should be investigated. Third, the concentrations of
uremic toxins in culture medium for HepG2 cells were an
arbitrary simplex.
Conclusions
The major findings of the present study are that the
uremic toxins, more than inflammatory cytokines, play
inhibitory roles in DIO1 enzyme activity, which then
provides negative feedback to the growing concentra-
tions of inflammatory cytokines.
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